Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sarepta Therapeutics, Inc.
Report date December 11, 2020 · Filed December 15, 2020
Section 16 reporting ended · disclosed 2020-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,140 |
Ending reported balance
After 2020-12-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-11 · Exercise / conversion · Acquired 1,115 · Balance 9,255 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 2 · 2020-12-11 · Sale · Disposed 1,115 · Balance 8,140 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.45 · Expires 2028-03-05 | Direct | 12,285 |
Reported balance
After 2020-12-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-11 · Exercise / conversion · Disposed 1,115 · Balance 12,285 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2020 Filed Dec 15, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 1,115 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-20-063355 · doc4.xml · derivative · entry 3 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,285 Underlying: Common Stock · 1,115 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,115 | $165.00 | $183,975.00 |
DisclosureSEC source: 0001209191-20-063355 · doc4.xml · nonDerivative · entry 2 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,140 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,115 | $71.45 | $79,666.75 |
DisclosureSEC source: 0001209191-20-063355 · doc4.xml · nonDerivative · entry 1 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 01:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-062807 · doc4.xml · derivative · entry 3 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,125 shares Expires 2027-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 01:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,125 | $160.00 | $180,000.00 |
DisclosureSEC source: 0001209191-20-062807 · doc4.xml · nonDerivative · entry 2 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,140 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 01:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,125 | $29.60 | $33,300.00 |
DisclosureSEC source: 0001209191-20-062807 · doc4.xml · nonDerivative · entry 1 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2 · balance_after: Amount of Securities Beneficially Owned includes 308 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2020. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-045321 · doc4.xml · derivative · entry 3 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,125 shares Expires 2027-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 1,125 | $155.00 | $174,375.00 |
DisclosureSEC source: 0001209191-20-045321 · doc4.xml · nonDerivative · entry 2 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,832 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| August 03, 2020 Filed Aug 6, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,125 | $29.60 | $33,300.00 |
DisclosureSEC source: 0001209191-20-045321 · doc4.xml · nonDerivative · entry 1 Bratica Joseph · CIK 0001820070 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.